Why the study?
Does the use of contemporary antidiabetic therapies (GLP-1 receptor agonists or SGLT-2 inhibitors) improve glycemic control and cardiovascular-renal parameters compared to conventional therapies in adults with type 2 diabetes mellitus?
Observational (n=250)
Does the use of contemporary antidiabetic therapies (GLP-1 receptor agonists or SGLT-2 inhibitors) improve glycemic control and cardiovascular-renal parameters compared to conventional therapies in adults with type 2 diabetes mellitus?
In a real-world cohort of adults with type 2 diabetes, contemporary therapies like GLP-1 receptor agonists and SGLT-2 inhibitors showed favorable but non-significant numerical trends in cardiometabolic profiles compared to conventional therapies.
Background: Contemporary antidiabetic therapy has evolved from a glucose-centered approach toward integrated cardiometabolic risk reduction. However, real-world evidence regarding treatment patterns and their association with glycemic and cardiovascular–renal profiles remain limited. Methods: This retrospective observational study included 250 adults with type 2 diabetes mellitus receiving non-insulin glucose-lowering therapy in routine specialist clinical practice. Demographic, clinical, biochemical, and pharmacological data were extracted from medical records. Glycemic control was assessed using HbA1c levels and HbA1c variation, while cardiovascular–renal parameters included estimated glomerular filtration rate (eGFR), C-reactive protein (CRP), lipid profile, blood pressure, and heart failure prevalence. Comparative analyses and multivariate logistic regression were performed. Results: The cohort had a mean age of 61.8 ± 11.3 years, and all patients had type 2 diabetes mellitus (100.0%). Obesity, metabolic syndrome, hypertension, ischemic heart disease, and chronic kidney disease were highly prevalent. Metformin was the most frequently prescribed therapy (58.8%), followed by GLP-1 receptor agonists (28.8%) and SGLT-2 inhibitors (27.6%). Patients receiving GLP-1 receptor agonists or SGLT-2 inhibitors showed numerically lower HbA1c values and greater HbA1c reductions compared with conventional therapies. However, differences in HbA1c, CRP, and eGFR were not statistically significant after correction for multiple comparisons. Longer diabetes duration independently predicted poor glycemic control, whereas increasing age was associated with a lower probability of HbA1c > 7%. Conclusions: Contemporary antidiabetic therapies were associated with favorable numerical cardiometabolic trends, although these associations did not remain statistically significant after multiple-comparison correction. The findings should therefore be considered exploratory and hypothesis-generating.
No takes yet. Share an insight, caveat, or question.
Moisi et al. (2026) conducted an observational in Type 2 diabetes mellitus (n=250). GLP-1 receptor agonists or SGLT-2 inhibitors vs. Conventional therapies was evaluated on HbA1c, CRP, and eGFR (p=not significant).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: